Kim D Vandegriff

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Sangart, Inc., University of California, Other. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kim D Vandegriff. Retrieved from https://idiyas.com/inventor/kim-d-vandegriff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 72.2

CIPO Patents = 6

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 128(Granted Patents)

Location History:

San Diego, CA (US) (2001 - 2020)
Santa Fe, NM (US) (2018 - 2022)

Company Filing History:

University of California

patents

5 out of 834,513

Other

patents

Years Active: 2001-2022

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11359004 - Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins (2022-06-14),

2. 10821158 - Polyalkylene oxide valerate hemoglobin conjugates (2020-11-03),

3. 10029001 - Diaspirin crosslinked pegylated hemoglobin (2018-07-24),

4. 9493616 - Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios (2016-11-15),

5. 9241979 - Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin (2016-01-26),

6. 9138463 - MalPEG-Hb conjugate-containing compositions for delivering carbon monoxide (CO) to cells (2015-09-22),

7. 8609815 - Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant (2013-12-17),

8. 8377868 - Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin (2013-02-19),

9. 8278275 - Method to enhance hemodynamic stability using oxygen carrying compositions (2012-10-02),

10. 8021858 - Method for making polyalkylene oxide modified hemoglobin (2011-09-20),

11. 7989414 - Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin (2011-08-02),

12. 7625862 - Method for making a high oxygen affinity modified hemoglobin for oxygen transport (2009-12-01),

13. 7622439 - Method to enhance hemodynamic stability using oxygen carrying compositions (2009-11-24),

14. 7271145 - Methods and compositions for oxygen transport comprising modified hemoglobin in plasma (2007-09-18),

15. 6974795 - Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin (2005-12-13),

Title: Kim D. Vandegriff: Innovator in Protein Nitroxylation

Introduction

Kim D. Vandegriff is a distinguished inventor based in San Diego, CA, whose work has significantly advanced the field of biochemistry, particularly in the synthesis and application of nitroxylated proteins. With a prolific portfolio of 18 patents, Kim has made remarkable contributions to the development of therapeutics involving hemoglobin and related compounds.

Latest Patents

Among Kim D. Vandegriff's latest innovations are two notable patents. The first, titled "Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins," describes innovative methods for synthesizing succinimide-activated nitroxyl compounds. This invention allows for the preparation of nitroxylated proteins, including nitroxylated heme proteins such as hemoglobin and myoglobin. These nitroxylated proteins can be further conjugated to polyalkylene oxides, such as polyethylene glycol (PEG), to enhance their utility as oxygen therapeutic agents (OTAs). Additionally, the invention details pharmaceutical compositions featuring these nitroxylated proteins and outlines methods for their use in treating various medical conditions.

The second patent, "Polyalkylene oxide valerate hemoglobin conjugates," focuses on the creation of polyethylene glycol (PEG) conjugated hemoglobins. This involves the conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and N-terminal valines of hemoglobin, further expanding the possibilities for therapeutic applications in oxygen delivery.

Career Highlights

Throughout his career, Kim D. Vandegriff has excelled in research and development roles, notably with companies such as Sangart, Inc. His expertise in biochemistry and protein modification has positioned him as a leader in the field, contributing significantly to the advancement of innovative medical solutions.

Collaborations

Kim has collaborated with several notable professionals, including Robert M. Winslow and Ashok Malavalli. These partnerships have enhanced his research endeavors, fostering a collaborative environment that promotes innovation and the sharing of ideas in scientific exploration.

Conclusion

In summary, Kim D. Vandegriff stands out as an innovative inventor whose contributions to nitroxylation and protein therapeutic development are impactful. With a dedicated focus on enhancing protein functionality through novel chemical modifications, he is set to continue influencing the landscape of biochemistry and medicine. His work exemplifies the importance of innovation in addressing complex biological challenges.

Profile summary based on public USPTO records.